@Article{,
AUTHOR = {Anita W. Rijneveld, Sandrine Florquin, Peter Speelman, Carl K. Edwards, Charles A. Dinarello, Tom van der Poll},
TITLE = {Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia},
JOURNAL = {European Cytokine Network},
VOLUME = {14},
YEAR = {2003},
NUMBER = {4},
PAGES = {242--245},
URL = {http://www.techscience.com/ECN/v14n4/66523},
ISSN = {1952-4005},
ABSTRACT = {The inhibition of the biological activity of IL-1 by recombinant human IL-1 receptor antagonist
(IL-1ra) has been investigated in several, controlled clinical trials. Encouraging results have been reported, in
particular in patients with rheumatoid arthritis. In the present study, we investigated the influence of treatment
of wild type mice with IL-1ra, which resulted in an incomplete and transient inhibition of IL-1 activity. Treatment
with recombinant human IL-1ra resulted in an enhanced bacterial outgrowth in the lungs of BALB/c and
C57BL/6 mice early after induction of pneumococcal pneumonia, without influencing survival or the pulmonary
inflammatory response. The effect of IL-1ra on the host response to <i>S. pneumoniae</i> pneumonia is modest and
transient. The present data, together with the findings in IL-1R−/− mice in earlier work, suggest that IL-1 occupies
a role in the pulmonary immune response to <i>S. pneumoniae</i> that is substantially less prominent than that of
TNF-α.},
DOI = {}
}